Velo3D, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Velo3D, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.97M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $41.00M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $77.44M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $78.71M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $27.44M | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | $0 | May 12, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.97M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $41.00M | Mar 31, 2026 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.40M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.09M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($26.27M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $843.0K | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $4.96M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $6.37M | Mar 28, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($71.36M) | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | ($11.19M) | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | ($13.26M) | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | ($25.01M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($69.74M) | Mar 31, 2026 |
| FY2025 | Sep 30, 2024 | ($21.88M) | Mar 31, 2026 |
| FY2025 | Jun 30, 2024 | $935.0K | Mar 31, 2026 |
| FY2025 | Mar 31, 2024 | ($27.52M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($135.14M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.97M | Apr 3, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($54.92M) | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | ($9.99M) | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | ($11.60M) | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | ($11.52M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($78.79M) | Mar 31, 2026 |
| FY2025 | Sep 30, 2024 | ($17.63M) | Mar 31, 2026 |
| FY2025 | Jun 30, 2024 | ($19.41M) | Mar 31, 2026 |
| FY2025 | Mar 31, 2024 | ($20.66M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($133.25M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($106.31M) | Apr 3, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.65M | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | $2.72M | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | $2.59M | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | $2.06M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $15.48M | Mar 31, 2026 |
| FY2025 | Sep 30, 2024 | $3.88M | Mar 31, 2026 |
| FY2025 | Jun 30, 2024 | $4.04M | Mar 31, 2026 |
| FY2025 | Mar 31, 2024 | $4.67M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $42.03M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $46.27M | Apr 3, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.33M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($32.68M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($105.64M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($123.96M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($56.40M) | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | ($782.4K) | May 12, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.72M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.82M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $9.62M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $401.0K | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $105.35M | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | $93.66M | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | $78.40M | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | $91.32M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $89.18M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $153.80M | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | $227.18M | Apr 3, 2024 |
| FY2023 | Jun 30, 2023 | $204.62M | Apr 3, 2024 |
| FY2023 | Mar 31, 2023 | $211.55M | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $223.06M | Apr 3, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.19M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $49.52M | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | $76.37M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $85.46M | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | $128.48M | Apr 3, 2024 |
| FY2023 | Jun 30, 2023 | $96.21M | Apr 3, 2024 |
| FY2023 | Mar 31, 2023 | $91.79M | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $84.27M | Apr 3, 2024 |
| FY2023 | Sep 30, 2022 | $144.61M | Apr 3, 2024 |
| FY2023 | Jun 30, 2022 | $80.83M | Apr 3, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.16M | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | $29.91M | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | $21.37M | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | $32.80M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $39.66M | Mar 31, 2026 |
| FY2024 | Sep 30, 2024 | $34.42M | Mar 31, 2025 |
| FY2025 | Dec 31, 2023 | $68.34M | Mar 31, 2026 |
| FY2023 | Sep 30, 2023 | $98.71M | Apr 3, 2024 |
| FY2023 | Jun 30, 2023 | $108.42M | Apr 3, 2024 |
| FY2023 | Mar 31, 2023 | $119.76M | Apr 3, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($498.14M) | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | ($476.25M) | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | ($465.06M) | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | ($451.80M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($426.78M) | Mar 31, 2026 |
| FY2025 | Sep 30, 2024 | ($405.51M) | Mar 31, 2026 |
| FY2025 | Jun 30, 2024 | ($383.63M) | Mar 31, 2026 |
| FY2025 | Mar 31, 2024 | ($384.56M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($357.04M) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | ($300.89M) | Apr 3, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.01M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.21M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $24.49M | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | $58.13M | Apr 3, 2024 |
| FY2023 | Jun 30, 2023 | $28.87M | Apr 3, 2024 |
| FY2023 | Mar 31, 2023 | $37.14M | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $31.98M | Apr 3, 2024 |
| FY2023 | Sep 30, 2022 | $40.35M | Apr 3, 2024 |
| FY2023 | Jun 30, 2022 | $43.51M | Apr 3, 2024 |
| FY2023 | Mar 31, 2022 | $104.43M | Apr 3, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.02M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $5.99M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $44.00M | Apr 3, 2024 |
| FY2022 | Dec 31, 2022 | $8.36M | Mar 20, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (82) | Mar 31, 2026 |
| FY2025 | Sep 30, 2024 | (35) | Mar 31, 2026 |
| FY2025 | Jun 30, 2024 | 1 | Mar 31, 2026 |
| FY2025 | Mar 31, 2024 | (55) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 3, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 31, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Mar 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (82) | Mar 31, 2026 |
| FY2025 | Sep 30, 2024 | (35) | Mar 31, 2026 |
| FY2025 | Jun 30, 2024 | 1 | Mar 31, 2026 |
| FY2025 | Mar 31, 2024 | (55) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 3, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.61M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 12.99M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 7.38M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 187.56M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | 183.23M | Mar 20, 2023 |
| FY2022 | Sep 29, 2021 | 183.16M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 16.00M | Mar 28, 2022 |